Why Is Kodiak Sciences $KOD Stock Up +125.44% Today? (Find out why any stock moved today on Tickeron.) • $KOD shares surged roughly 125%, trading near $72.93 in morning action versus a prior close of $32.35. • The primary catalyst was positive topline data from the Phase 3 DAYBREAK study in wet age-related macular degeneration (AMD). • Both investigational therapies, Zenkuda and KSI-501, met their primary endpoints for non-inferiority in visual acuity versus aflibercept (Eylea). • The move came on a company-specific catalyst, with major U.S. indexes trading lower on the day. Investors are now watching Kodiak's planned regulatory submission, expected in the fourth quarter of 2026. $OCUL $RGNX $KYMR $EYPT $RYTM $PVLA